Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASECOVID
2024-520308-24-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bevacizumab in post-COVID syndrome, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Improvement in impaired DLCO at 3 months. Planned start Oct 2025; status: authorised.
02
Drugs
bevacizumab
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2024-520308-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520308-24-00.